Wide Ranks

ITCI

Intra-Cellular Therapies Inc.

86.59

Top Statistics
Market Cap 9 B Forward PE 420.07 Revenue Growth 39.00 %
Current Ratio 7.66 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -14.07 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -67.65 Enterprise / Revenue 13.35 Price To Sales Trailing12 Months 14.96
Profitability
Profit Margins -14.07 % Operating Margins -22.15 %
Balance Sheet
Total Cash 1 B Total Cash Per Share 9.49 Total Debt 17 M
Total Debt To Equity 1.55 Current Ratio 7.66 Book Value Per Share 10.80
All Measures
Short Ratio 260.00 % Message Board Id finmb_9425271 Shares Short Prior Month 2 M
Return On Equity -0.0990 City New York Uuid 663c5e9c-25b0-3a49-b384-beebac54b1ca
Previous Close 86.43 First Trade Date Epoch Utc 1 B Book Value 10.80
Beta 0.9730 Total Debt 17 M Volume 397850
Price To Book 8.02 Fifty Two Week Low 58.92 Total Cash Per Share 9.49
Total Revenue 613 M Shares Short Previous Month Date 1 B Target Median Price 100.00
Max Age 86400 Recommendation Mean 1.56 Sand P52 Week Change 0.3133
Operating Margins -22.15 % Target Mean Price 101.87 Net Income To Common -86370000
Short Percent Of Float 0.0197 Implied Shares Outstanding 106 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 493050 Average Volume10days 493050
Total Cash 1 B Next Fiscal Year End 1 B Revenue Per Share 6.10
Held Percent Insiders 0.0233 Ebitda Margins -19.73 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 86.43
Target Low Price 79.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 79.91
Open 85.57 Free Cashflow -6946125 State NY
Dividend Yield 0.00 % Return On Assets -0.0745 Time Zone Short Name EST
Trailing Eps -0.8700 Day Low 85.27 Address1 430 East 29th Street
Shares Outstanding 106 M Price Hint 2 Target High Price 135.00
Website https://www.intracellulartherapies.com 52 Week Change 0.4109 Average Volume 560470
Forward Eps 0.2600 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 693.60 % Is_sp_500 False Regular Market Day High 86.78
Profit Margins -14.07 % Debt To Equity 1.55 Fifty Two Week High 93.45
Day High 86.78 Shares Short 1 M Regular Market Open 85.57
Industry Key drug-manufacturers-specialty-generic Earnings Growth 0.00 % Enterprise To Revenue 13.35
Revenue Growth 39.00 % Shares Percent Shares Out 0.0172 Operating Cashflow -62160000
Currency USD Time Zone Full Name America/New_York Market Cap 9 B
Is_nasdaq_100 False Zip 10016 Quote Type EQUITY
Industry Drug Manufacturers - Specialty & Generic Long Name Intra-Cellular Therapies, Inc. Regular Market Day Low 85.27
Held Percent Institutions 0.9602 Current Price 86.59 Enterprise To Ebitda -67.65
Financial Currency USD Current Ratio 7.66 Gross Margins 57.01 %
Industry Disp Drug Manufacturers - Specialty & Generic Number Of Analyst Opinions 15 Country United States
Float Shares 103 M Two Hundred Day Average 73.56 Enterprise Value 8 B
Price To Sales Trailing12 Months 14.96 Forward PE 420.07 Regular Market Volume 397850
Ebitda -121086000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.

The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults.

It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications.

In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders.

Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.